Melanoma biology and new targeted therapy

被引：1078

作者：

Gray-Schopfer, Vanessa ^{[1
]}

Wellbrock, Claudia ^{[1
]}

Marais, Richard ^{[1
]}

机构：

[1] Canc Res UK, Inst Canc Res, Signal Transduct Team, Ctr Cell & Mol Biol, London SW3 6JB, England

来源：

NATURE | 2007年 / 445卷 / 7130期

关键词：

D O I：

10.1038/nature05661

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Melanoma is a cancer that arises from melanocytes, specialized pigmented cells that are found predominantly in the skin. The incidence of melanoma is rising steadily in western populations - the number of cases worldwide has doubled in the past 20 years. In its early stages malignant melanoma can be cured by surgical resection, but once it has progressed to the metastatic stage it is extremely difficult to treat and does not respond to current therapies. Recent discoveries in cell signalling have provided greater understanding of the biology that underlies melanoma, and these advances are being exploited to provide targeted drugs and new therapeutic approaches.

引用

收藏

页码：851 / 857

页数：7

相关论文

共 101 条

[21] Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity [J].

Del Bufalo, D ;

Trisciuoglio, D ;

Scarsella, M ;

Zangemeister-Wittke, U ;

Zupi, G .

ONCOGENE, 2003, 22 (52) :8441-8447

[22] Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin [J].

Dias, SD ;

Friedlos, F ;

Light, Y ;

Springer, C ;

Workman, P ;

Marais, R .

CANCER RESEARCH, 2005, 65 (23) :10686-10691

[23] In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling [J].

Dumaz, Nicolas ;

Hayward, Robert ;

Martin, Jan ;

Ogilvie, Lesley ;

Hedley, Douglas ;

Curtin, John A. ;

Bastian, Boris C. ;

Springer, Caroline ;

Marais, Richard .

CANCER RESEARCH, 2006, 66 (19) :9483-9491

[24] Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis [J].

Eisen, T. ;

Ahmad, T. ;

Flaherty, K. T. ;

Gore, M. ;

Kaye, S. ;

Marais, R. ;

Gibbens, I. ;

Hackett, S. ;

James, M. ;

Schuchter, L. M. ;

Nathanson, K. L. ;

Xia, C. ;

Simantov, R. ;

Schwartz, B. ;

Poulin-Costello, M. ;

O'Dwyer, P. J. ;

Ratain, M. J. .

BRITISH JOURNAL OF CANCER, 2006, 95 (05) :581-586

[25] Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma [J].

Ellerhorst, J. A. ;

Ekmekcioglu, S. ;

Johnson, M. K. ;

Cooke, C. P. ;

Johnson, M. M. ;

Grimm, E. A. .

ONCOGENE, 2006, 25 (28) :3956-3962

[26]

End DW, 2001, CANCER RES, V61, P131

[27] Chemotherapy and targeted therapy combinations in advanced melanoma [J].

Flaherty, KT .

CLINICAL CANCER RESEARCH, 2006, 12 (07) :2366S-2370S

[28]

Fry DW, 2004, MOL CANCER THER, V3, P1427

[29] Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization [J].

Garnett, MJ ;

Rana, S ;

Paterson, H ;

Barford, D ;

Marais, R .

MOLECULAR CELL, 2005, 20 (06) :963-969

[30] Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma [J].

Garraway, LA ;

Widlund, HR ;

Rubin, MA ;

Getz, G ;

Berger, AJ ;

Ramaswamy, S ;

Beroukhim, R ;

Milner, DA ;

Granter, SR ;

Du, JY ;

Lee, C ;

Wagner, SN ;

Li, C ;

Golub, TR ;

Rimm, DL ;

Meyerson, ML ;

Fisher, DE ;

Sellers, WR .

NATURE, 2005, 436 (7047) :117-122

← 1 2 3 4 5 6 7 8 9 10 →